Constant Therapeutics LLC, specializing in biopharmaceuticals, announced the first patient dosed in their Phase 2 trial of TXA127, a peptide therapy aimed at improving post-stroke recovery.

Pfizer and Genmab announced the FDA has accepted their supplemental application for TIVDAK.

Fate Therapeutics Reveals Commencement of Initial Human Trial for FT825 / ONO-8250 in Individuals Suffering from HER2-positive Progressive Solid Cancers.

Astellas Pharma Inc. announced on Jan 4, 2024, the FDA issued a complete response to their zolbetuximab Biologics License Application.

Medison Pharma and Regeneron Ireland DAC have formed an exclusive partnership for Medison to distribute Regeneron's innovative treatment, Libtayo® (cemiplimab).

Lutikizumab Demonstrates Encouraging Outcomes in Phase 2 Study Among Individuals with Moderate to Advanced Hidradenitis Suppurativa, Progressing to Next Trial Stage.

Innovent declared the successful completion of the initial stage 3 clinical evaluation for Mazdutide among overweight and obese adults in China.

The EU Commission has approved Eylea™ 8 mg, an 8 mg aflibercept (114.3 mg/ml) injectable, for treating neovascular age-related macular degeneration and diabetic macular edema-related vision loss.

Bayer announced positive early results from Phase III OASIS 1 and 2 trials, where the experimental drug elinzanetant outperformed placebo.

Curevo Vaccine has reported its second-phase study for Amezosvatein, This advanced shingles immunization demonstrates effectiveness against Shingrix in direct comparison.

OKYO Pharma Corporation has disclosed that OK-101 has met its primary efficacy benchmarks in Phase 2 human trials, demonstrating statistical relevance in treating dry eye condition.

Novartis' Scemblix® outperforms traditional therapy in achieving significant molecular remission in a Phase III study involving newly diagnosed chronic myeloid leukemia patients.